TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Rating of "Buy" from Brokerages

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight analysts that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $10.75.

TLSI has been the subject of several research reports. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday, March 28th. Lake Street Capital initiated coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They issued a "buy" rating and a $10.00 price target for the company.

TriSalus Life Sciences Stock Down 5.9%

Shares of TLSI traded down $0.33 during midday trading on Friday, hitting $5.25. The company had a trading volume of 40,871 shares, compared to its average volume of 42,323. The company's 50 day moving average price is $5.40 and its 200 day moving average price is $5.15. The stock has a market cap of $198.65 million, a price-to-earnings ratio of -2.11 and a beta of 0.47. TriSalus Life Sciences has a 52 week low of $3.50 and a 52 week high of $6.18.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The firm had revenue of $9.17 million for the quarter, compared to analyst estimates of $9.04 million. During the same period in the previous year, the business earned ($0.60) earnings per share. Equities analysts anticipate that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

Insider Buying and Selling at TriSalus Life Sciences

In other TriSalus Life Sciences news, insider Richard Marshak sold 6,597 shares of the business's stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $5.18, for a total transaction of $34,172.46. Following the completion of the transaction, the insider now directly owns 69,101 shares of the company's stock, valued at $357,943.18. The trade was a 8.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 16,125 shares of company stock valued at $83,528 in the last ninety days. Company insiders own 27.50% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in TriSalus Life Sciences by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 204,137 shares of the company's stock valued at $1,023,000 after purchasing an additional 3,710 shares during the period. Northern Trust Corp lifted its stake in shares of TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after acquiring an additional 5,936 shares during the period. Charles Schwab Investment Management Inc. acquired a new stake in shares of TriSalus Life Sciences in the 1st quarter worth approximately $55,000. Renaissance Technologies LLC acquired a new stake in shares of TriSalus Life Sciences in the 4th quarter worth approximately $67,000. Finally, Connective Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences in the 4th quarter worth approximately $140,000. 2.58% of the stock is owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.